bioRxiv preprint doi: https://doi.org/10.1101/735324; this version posted August 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Mutational signatures in upper tract urothelial carcinoma define etiologically distinct 2 subtypes with prognostic relevance 3 Xuesong Li1†, Huan Lu2,3†, Bao Guan 1,2,4,5†, Zhengzheng Xu2,3, Yue Shi2, Juan Li2,3, Wenwen 4 Kong2,3, Jin Liu6, Dong Fang1,5, Libo Liu1,4,5, Qi Shen1,4,5, Yanqing Gong1,4,5, Shiming He1,4,5, Qun 5 He1,4,5, Liqun Zhou 1,4,5* and Weimin Ci 2,3,7* 6 Affiliations: 7 1Department of Urology, Peking University First Hospital, Beijing 100034, China. 8 2Key Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, Chinese 9 Academy of Sciences, Beijing 100101, China; 10 3University of Chinese Academy of Sciences, Beijing 100049, China. 11 4Institute of Urology, Peking University, Beijing 100034, China. 12 5National Urological Cancer Center, Beijing, 100034, China. 13 6Department of Urology, The Third Hospital of Hebei Medical University, Hebei 050051, China. 14 7Institute of Stem cell and Regeneration, Chinese Academy of Sciences, Beijing 100101, China. 15 16 *Correspondence to:
[email protected]; and
[email protected]. 17 † These authors contributed equally to this work. 18 19 Keywords: 20 Upper tract urothelial carcinoma; Whole-genome sequencing; Mutational signature; Aristolochic 21 acid. 22 23 1 bioRxiv preprint doi: https://doi.org/10.1101/735324; this version posted August 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.